November 01, 2025

Get In Touch

COVAXIN Phase 2 Clinical Trial To Undergo At Gauhati Medical College

Guwahati: The Gauhati Medical College and Hospital (GMCH) has been selected for the second phase clinical testing of India's indigenously developed coronavirus vaccine, COVAXIN, Assam Health Minister Himanta Biswa Sarma said on Tuesday.
He said the GMCH would provide all-out support for the second phase clinical testing of COVAXIN, which has already shown successful results in phase-one clinical trials.
According to the Minister, till Tuesday night, Assam has tested more than 18.22 lakh samples with 79,667 people testing positive for Covid-19. Of the total cases, 56,734 people have recovered from the disease with the recovery rate being 71.2 per cent and mortality rate 0.25 per cent.
Sarma said 197 people have died due to Covid-19 in the state so far. In terms of recovery rate, he said, five states -- Delhi, Tamil Nadu, Gujarat, West Bengal and Tripura -- were better than Assam.

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!